156 related articles for article (PubMed ID: 15772700)
1. Evaluation of immunomodulatory treatment based on conventional and lineage-specific chimerism analysis in patients with myeloid malignancies after myeloablative allogeneic hematopoietic cell transplantation.
Zeiser R; Spyridonidis A; Wäsch R; Ihorst G; Grüllich C; Bertz H; Finke J
Leukemia; 2005 May; 19(5):814-21. PubMed ID: 15772700
[TBL] [Abstract][Full Text] [Related]
2. Chimerism and minimal residual disease monitoring after reduced intensity conditioning (RIC) allogeneic transplantation.
Pérez-Simón JA; Caballero D; Diez-Campelo M; Lopez-Pérez R; Mateos G; Cañizo C; Vazquez L; Vidriales B; Mateos MV; Gonzalez M; San Miguel JF
Leukemia; 2002 Aug; 16(8):1423-31. PubMed ID: 12145680
[TBL] [Abstract][Full Text] [Related]
3. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
4. Cytokine expression in tumors treated with donor lymphocyte infusions after allogeneic hematopoietic stem cell transplantation.
Conrad R; Remberger M; Cederlund K; Barkholt L
Immunotherapy; 2011 Mar; 3(3):443-51. PubMed ID: 21395385
[TBL] [Abstract][Full Text] [Related]
5. Serial and quantitative analysis of mixed hematopoietic chimerism by PCR in patients with acute leukemias allows the prediction of relapse after allogeneic BMT.
Bader P; Beck J; Frey A; Schlegel PG; Hebarth H; Handgretinger R; Einsele H; Niemeyer C; Benda N; Faul C; Kanz L; Niethammer D; Klingebiel T
Bone Marrow Transplant; 1998 Mar; 21(5):487-95. PubMed ID: 9535041
[TBL] [Abstract][Full Text] [Related]
6. Quantitative analysis of chimerism after allogeneic stem cell transplantation by real-time polymerase chain reaction with single nucleotide polymorphisms, standard tandem repeats, and Y-chromosome-specific sequences.
Koldehoff M; Steckel NK; Hlinka M; Beelen DW; Elmaagacli AH
Am J Hematol; 2006 Oct; 81(10):735-46. PubMed ID: 16838323
[TBL] [Abstract][Full Text] [Related]
7. Outcome and long-term follow-up of alloreactive donor lymphocyte infusions given for relapse after myeloablative allogeneic hematopoietic stem cell transplantations (HSCT).
Michallet AS; Nicolini F; Fürst S; Le QH; Dubois V; Hayette S; Bourgeot JP; Tremisi JP; Thomas X; Gebuhrer L; Michallet M
Bone Marrow Transplant; 2005 Mar; 35(6):601-8. PubMed ID: 15756285
[TBL] [Abstract][Full Text] [Related]
8. Chimerism status is a useful predictor of relapse after allogeneic stem cell transplantation for acute leukemia.
Barrios M; Jiménez-Velasco A; Román-Gómez J; Madrigal ME; Castillejo JA; Torres A; Heiniger A
Haematologica; 2003 Jul; 88(7):801-10. PubMed ID: 12857560
[TBL] [Abstract][Full Text] [Related]
9. Prompt initiation of immunotherapy in children with an increasing number of autologous cells after allogeneic HCT can induce complete donor-type chimerism: a report of 14 children.
Gorczyñska E; Turkiewicz D; Toporski J; Kalwak K; Rybka B; Ryczan R; Sajewicz L; Chybicka A
Bone Marrow Transplant; 2004 Jan; 33(2):211-7. PubMed ID: 14628077
[TBL] [Abstract][Full Text] [Related]
10. Leukemia lineage-specific chimerism analysis is a sensitive predictor of relapse in patients with acute myeloid leukemia and myelodysplastic syndrome after allogeneic stem cell transplantation.
Mattsson J; Uzunel M; Tammik L; Aschan J; Ringdén O
Leukemia; 2001 Dec; 15(12):1976-85. PubMed ID: 11753621
[TBL] [Abstract][Full Text] [Related]
11. [Relapse of childhood ALL, AML and MDS after allogeneic stem cell transplantation can be prevented by donor lymphocyte infusion in a critical stage of increasing mixed chimerism].
Beck JF; Klingebiel T; Kreyenberg H; Schaudt A; Wölle W; Niethammer D; Bader P
Klin Padiatr; 2002; 214(4):201-5. PubMed ID: 12165902
[TBL] [Abstract][Full Text] [Related]
12. [Quantitative analysis of donor chimerism in adoptive immunotherapy following allogeneic hematopoietic stem cell transplantation].
Tang XW; Wu DP; Sun AN; Zhu ZL; Chang WR; Ruan CG
Zhonghua Nei Ke Za Zhi; 2006 May; 45(5):359-62. PubMed ID: 16780733
[TBL] [Abstract][Full Text] [Related]
13. Leukemia lineage-specific chimerism analysis and molecular monitoring improve outcome of donor lymphocyte infusions.
Sairafi D; Remberger M; Uhlin M; Ljungman P; Ringdén O; Mattsson J
Biol Blood Marrow Transplant; 2010 Dec; 16(12):1728-37. PubMed ID: 20542125
[TBL] [Abstract][Full Text] [Related]
14. Reduced intensity conditioning and prophylactic DLI can cure patients with high-risk acute leukaemias if complete donor chimerism can be achieved.
Massenkeil G; Nagy M; Lawang M; Rosen O; Genvresse I; Geserick G; Dörken B; Arnold R
Bone Marrow Transplant; 2003 Mar; 31(5):339-45. PubMed ID: 12634724
[TBL] [Abstract][Full Text] [Related]
15. Chimerism-based pre-emptive immunotherapy with fast withdrawal of immunosuppression and donor lymphocyte infusions after allogeneic stem cell transplantation for pediatric hematologic malignancies.
Horn B; Petrovic A; Wahlstrom J; Dvorak CC; Kong D; Hwang J; Expose-Spencer J; Gates M; Cowan MJ
Biol Blood Marrow Transplant; 2015 Apr; 21(4):729-37. PubMed ID: 25644958
[TBL] [Abstract][Full Text] [Related]
16. Detailed monitoring of hematopoietic chimerism in a child treated by adoptive immunotherapy for high risk of relapse after BMT for acute myeloid leukemia.
Formánková R; Honzátková L; Sieglová Z; Starý J; Sedlácek P; Brdicka R
Bone Marrow Transplant; 2000 Feb; 25(4):453-6. PubMed ID: 10723591
[TBL] [Abstract][Full Text] [Related]
17. Increasing mixed chimerism defines a high-risk group of childhood acute myelogenous leukemia patients after allogeneic stem cell transplantation where pre-emptive immunotherapy may be effective.
Bader P; Kreyenberg H; Hoelle W; Dueckers G; Kremens B; Dilloo D; Sykora KW; Niemeyer C; Reinhardt D; Vormoor J; Gruhn B; Lang P; Greil J; Handgretinger R; Niethammer D; Klingebiel T; Beck JF
Bone Marrow Transplant; 2004 Apr; 33(8):815-21. PubMed ID: 14990984
[TBL] [Abstract][Full Text] [Related]
18. Chimerism analysis within 6 months of allogeneic stem cell transplantation predicts relapse in acute myeloid leukemia.
Huisman C; de Weger RA; de Vries L; Tilanus MG; Verdonck LF
Bone Marrow Transplant; 2007 Mar; 39(5):285-91. PubMed ID: 17262061
[TBL] [Abstract][Full Text] [Related]
19. Quantitative chimerism kinetics in relapsed leukemia patients after allogeneic hematopoietic stem cell transplantation.
Qin XY; Li GX; Qin YZ; Wang Y; Wang FR; Liu DH; Xu LP; Chen H; Han W; Wang JZ; Zhang XH; Li JL; Li LD; Liu KY; Huang XJ
Chin Med J (Engl); 2012 Jun; 125(11):1952-9. PubMed ID: 22884060
[TBL] [Abstract][Full Text] [Related]
20. Role of minimal residual disease and chimerism after reduced-intensity and myeloablative allo-transplantation in acute myeloid leukemia and high-risk myelodysplastic syndrome.
Bernal T; Diez-Campelo M; Godoy V; Rojas S; Colado E; Alcoceba M; González M; Vidriales B; Sánchez-Guijo FM; López-Corral L; Luño E; del Cañizo C
Leuk Res; 2014 May; 38(5):551-6. PubMed ID: 24655806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
